Saikosaponin B2

CAS# 58316-41-9

Saikosaponin B2

Catalog No. BCN5916----Order now to get a substantial discount!

Product Name & Size Price Stock
Saikosaponin B2:5mg $51.00 In Stock
Saikosaponin B2:10mg Please Inquire Instock
Saikosaponin B2:20mg Please Inquire Instock
Saikosaponin B2:50mg Please Inquire Instock
Related Products

Quality Control of Saikosaponin B2

Number of papers citing our products

Chemical structure

Saikosaponin B2

3D structure

Chemical Properties of Saikosaponin B2

Cas No. 58316-41-9 SDF Download SDF
PubChem ID 21637642 Appearance White powder
Formula C42H68O13 M.Wt 780.98
Type of Compound Triterpenoids Storage Desiccate at -20°C
Solubility Soluble in methanol; slightly soluble in water
Chemical Name (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES CC1C(C(C(C(O1)OC2CCC3(C(C2(C)CO)CCC4(C3C=CC5=C6CC(CCC6(C(CC54C)O)CO)(C)C)C)C)O)OC7C(C(C(C(O7)CO)O)O)O)O
Standard InChIKey WRYJYFCCMSVEPQ-ORAXXRKOSA-N
Standard InChI InChI=1S/C42H68O13/c1-21-29(47)34(55-35-32(50)31(49)30(48)24(18-43)53-35)33(51)36(52-21)54-28-11-12-38(4)25(39(28,5)19-44)10-13-40(6)26(38)9-8-22-23-16-37(2,3)14-15-42(23,20-45)27(46)17-41(22,40)7/h8-9,21,24-36,43-51H,10-20H2,1-7H3/t21-,24-,25-,26-,27-,28+,29+,30-,31+,32-,33-,34+,35+,36+,38+,39+,40-,41-,42-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Saikosaponin B2

The herb of Bupleurum chinense DC.

Biological Activity of Saikosaponin B2

DescriptionSaikosaponin B2 as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion. It (5 microM) induces differentiation of B16 melanoma cells, with potentiation of expressions of melanogenesis and tyrosinase.
TargetsHCV | PKC
In vitro

Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.[Pubmed: 25450204]

J Hepatol. 2015 Mar;62(3):541-8.

A vaccine against hepatitis C virus (HCV) is unavailable and cost-effective antivirals that prevent HCV infection and re-infection, such as in the transplant setting, do not exist. In a search for novel and economical prophylactic agents, we examined the antiviral activity of saikosaponins (SSa, SSb2, SSc, and SSd) from Bupleurum kaoi root (BK) as entry inhibitors against HCV infection.
METHODS AND RESULTS:
Infectious HCV culture systems were used to examine the effect of saikosaponins on the complete virus life cycle (entry, RNA replication/translation, and particle production). Antiviral activity against various HCV genotypes, clinical isolates, and infection of primary human hepatocytes were also evaluated. BK and the saikosaponins potently inhibited HCV infection at non-cytotoxic concentrations. These natural agents targeted early steps of the viral life cycle, while leaving replication/translation, egress, and spread relatively unaffected. In particular, we identified Saikosaponin B2(SSb2) as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion. Binding analysis, using soluble viral glycoproteins, demonstrated that SSb2 acted on HCV E2. Moreover, SSb2 inhibited infection by several genotypic strains and prevented binding of serum-derived HCV onto hepatoma cells. Finally, treatment with the compound blocked HCV infection of primary human hepatocytes.
CONCLUSIONS:
Due to its potency, SSb2 may be of value for development as an antagonist of HCV entry and could be explored as prophylactic treatment during the course of liver transplantation.

Protocol of Saikosaponin B2

Cell Research

Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity.[Pubmed: 8605013]

Biochem Biophys Res Commun. 1996 Feb 15;219(2):480-5.

Saikosaponin B2 (SSb2)was found to inhibit the proliferation of B16 melanoma cells.
METHODS AND RESULTS:
To explore this mechanism, we employed flow cytometry to determine the distribution of DNA content. The cell cycle of B16 melanoma cells was accumulated in the G1 phase followed by induction of apoptosis. This suggests that SSb2-induced proliferation inhibition is caused by G1 phase accumulation and that apoptosis induction is G1-phase-accumulation dependent. Phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, did not interfere with the proliferation and did not induce apoptosis of B16 melanoma cells by itself. However, PMA significantly abolished these effects of SSb2 in including proliferation inhibition and apoptosis induction.
CONCLUSIONS:
Down-regulation of the PKC activity may be involved in the effect of SSb2.

Saikosaponin B2 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Saikosaponin B2 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Saikosaponin B2

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.2804 mL 6.4022 mL 12.8044 mL 25.6089 mL 32.0111 mL
5 mM 0.2561 mL 1.2804 mL 2.5609 mL 5.1218 mL 6.4022 mL
10 mM 0.128 mL 0.6402 mL 1.2804 mL 2.5609 mL 3.2011 mL
50 mM 0.0256 mL 0.128 mL 0.2561 mL 0.5122 mL 0.6402 mL
100 mM 0.0128 mL 0.064 mL 0.128 mL 0.2561 mL 0.3201 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Saikosaponin B2

Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity.[Pubmed:8605013]

Biochem Biophys Res Commun. 1996 Feb 15;219(2):480-5.

Saikosaponin (SS) b2 was found to inhibit the proliferation of B16 melanoma cells. To explore this mechanism, we employed flow cytometry to determine the distribution of DNA content. The cell cycle of B16 melanoma cells was accumulated in the G1 phase followed by induction of apoptosis. This suggests that SSb2-induced proliferation inhibition is caused by G1 phase accumulation and that apoptosis induction is G1-phase-accumulation dependent. Phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, did not interfere with the proliferation and did not induce apoptosis of B16 melanoma cells by itself. However, PMA significantly abolished these effects of SSb2 in including proliferation inhibition and apoptosis induction. Down-regulation of the PKC activity may be involved in the effect of SSb2.

Saikosaponin b2 induces differentiation without growth inhibition in cultured B16 melanoma cells.[Pubmed:9872567]

Cell Struct Funct. 1998 Oct;23(5):265-72.

Treatment with 5 microM of saikosaponin (SS) b2 for 30 days was found to induce differentiation of B16 melanoma cells, with potentiation of expressions of melanogenesis and tyrosinase. To explore the mechanism of this effect, we observed the cell growth, cell cycle and morphology, and found that SSb2 did not affect any of these parameters. That is, SSb2 induced the differentiation of B16 melanoma cells without growth inhibition or cytotoxicity under conditions of low dose and long-term treatment. Phorbol ester, a protein kinase C (PKC) activator, markedly inhibited the expressions of melanogenesis and tyrosinase in both the control B16 melanoma cells and the long-term treated B16 melanoma cells. Down-regulation of the PKC activity may be involved in the effects of SSb2.

Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.[Pubmed:25450204]

J Hepatol. 2015 Mar;62(3):541-8.

BACKGROUND & AIMS: A vaccine against hepatitis C virus (HCV) is unavailable and cost-effective antivirals that prevent HCV infection and re-infection, such as in the transplant setting, do not exist. In a search for novel and economical prophylactic agents, we examined the antiviral activity of saikosaponins (SSa, SSb2, SSc, and SSd) from Bupleurum kaoi root (BK) as entry inhibitors against HCV infection. METHODS: Infectious HCV culture systems were used to examine the effect of saikosaponins on the complete virus life cycle (entry, RNA replication/translation, and particle production). Antiviral activity against various HCV genotypes, clinical isolates, and infection of primary human hepatocytes were also evaluated. RESULTS: BK and the saikosaponins potently inhibited HCV infection at non-cytotoxic concentrations. These natural agents targeted early steps of the viral life cycle, while leaving replication/translation, egress, and spread relatively unaffected. In particular, we identified SSb2 as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion. Binding analysis, using soluble viral glycoproteins, demonstrated that SSb2 acted on HCV E2. Moreover, SSb2 inhibited infection by several genotypic strains and prevented binding of serum-derived HCV onto hepatoma cells. Finally, treatment with the compound blocked HCV infection of primary human hepatocytes. CONCLUSIONS: Due to its potency, SSb2 may be of value for development as an antagonist of HCV entry and could be explored as prophylactic treatment during the course of liver transplantation.

Description

Saikosaponin B2 is an active component from Bupleurum kaoi root, acts as an entry inhibitor against HCV infection. Anti-cancer activity.

Keywords:

Saikosaponin B2,58316-41-9,Natural Products, buy Saikosaponin B2 , Saikosaponin B2 supplier , purchase Saikosaponin B2 , Saikosaponin B2 cost , Saikosaponin B2 manufacturer , order Saikosaponin B2 , high purity Saikosaponin B2

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: